Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the target of a significant increase in short interest in February. As of February 27th, there was short interest totaling 11,553 shares, an increase of 14.8% from the February 12th total of 10,060 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average trading volume of 12,784 shares, the short-interest ratio is presently 0.9 days. Based on an average trading volume of 12,784 shares, the short-interest ratio is presently 0.9 days. Currently, 0.5% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aptorum Group in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Aptorum Group Stock Performance

APM stock opened at $0.79 on Tuesday. The company’s 50 day moving average price is $0.88 and its 200 day moving average price is $1.31. Aptorum Group has a fifty-two week low of $0.65 and a fifty-two week high of $4.47.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.